MorphoSys AG (MOR): Price and Financial Metrics
MOR Price/Volume Stats
| Current price | $18.96 | 52-week high | $19.50 |
| Prev. close | $18.51 | 52-week low | $4.18 |
| Day low | $18.38 | Volume | 19,100 |
| Day high | $19.15 | Avg. volume | 1,019,393 |
| 50-day MA | $18.41 | Dividend yield | N/A |
| 200-day MA | $14.43 | Market Cap | 2.86B |
MOR Stock Price Chart Interactive Chart >
MorphoSys AG (MOR) Company Bio
MorphoSys AG engages in the research, development, and optimization of therapeutic antibody drug candidates in partnership with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 drugs for the treatment of cancer, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation. The company was founded in 1992 and is based in Planegg, Germany.
Latest MOR News From Around the Web
Below are the latest news stories about MORPHOSYS AG that investors may wish to consider to help them evaluate MOR as an investment opportunity.
Optimistic Investors Push MorphoSys AG (ETR:MOR) Shares Up 48% But Growth Is LackingMorphoSys AG ( ETR:MOR ) shareholders would be excited to see that the share price has had a great month, posting a 48... |
MorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 StudyPLANEGG/MUNICH, Germany, December 11, 2023--MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced comprehensive results from the Phase 3 MANIFEST-2 study investigating pelabresib, an investigational BET inhibitor, in combination with the JAK inhibitor ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis. These findings were presented in an oral presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, California. |
Further weakness as MorphoSys (ETR:MOR) drops 39% this week, taking five-year losses to 84%Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We don't wish... |
MorphoSys (MOR) Down 22% on Mixed Data From Myelofibrosis StudyThough data from the late study shows that treatment with MorphoSys' (MOR) combination therapy met its primary goal, it did not meet a secondary endpoint. |
FSR Stock Alert: Fisker Receives Non-Compliance Notice From NYSEFisker stock is falling on Tuesday as FSR investors react to a non-compliance notice and the resignation of its new CAO. |
MOR Price Returns
| 1-mo | N/A |
| 3-mo | 3.61% |
| 6-mo | 4.81% |
| 1-year | 135.82% |
| 3-year | 58.26% |
| 5-year | -35.07% |
| YTD | 91.52% |
| 2023 | 176.54% |
| 2022 | -62.00% |
| 2021 | -66.76% |
| 2020 | -20.55% |
| 2019 | 40.99% |
Continue Researching MOR
Here are a few links from around the web to help you further your research on MorphoSys AG's stock as an investment opportunity:MorphoSys AG (MOR) Stock Price | Nasdaq
MorphoSys AG (MOR) Stock Quote, History and News - Yahoo Finance
MorphoSys AG (MOR) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...